Designing Preclinical Experiments That Hold Up, Even on a Tight Budget
High capital intensity is one of the most consistently cited challenges facing India's biotech sector, and it's a real constraint, not an excuse founders invent. Syngene's own industry analysis is blunt about the underlying economics: outsourcing to an established CRDMO delivers roughly 90% faster startup time, 70-80% lower workforce cost, and 85% lower infrastructure setup cost than building comparable capability in-house. For a small or mid-scale funded company, building your own GLP-grade facility and full-time specialist team simply isn't a rational choice.
But capital intensity and data quality get conflated far more often than they should be. Some rigour genuinely requires money. But a large part of rigour also requires deciding, deliberately, to build good design discipline into a process.
Separating the cost-driven cuts from the free ones
The place to start isn't "what can we afford to cut," but "what actually costs money here, and what doesn't." A surprising amount of what determines whether preclinical data holds up under scrutiny falls into the second category.
What genuinely costs money
Larger sample sizes cost more: more animals, more reagents, more facility time. Redundant confirmatory studies, running a key experiment more than once to confirm a result before committing further capital, is a real, sometimes unavoidable expense. Premium facilities and specialized equipment carry real costs that don't disappear because a company is early-stage.
These are legitimate places where capital constraints force real tradeoffs, and no amount of clever process design eliminates them entirely.
What costs close to nothing
Randomization and blinding. Assigning animals or samples to treatment groups randomly and blinding whoever is assessing outcomes to which group they're looking at, costs essentially nothing beyond a bit of process discipline. Yet failures here, poor study design and inadequate bias control, are consistently identified as major contributors to translational failure in the scientific literature. This is likely the single highest-leverage, lowest-cost fix available to any team, regardless of budget size.
Pre-specifying the primary endpoint. Deciding what counts as a successful result before the experiment runs, rather than after the data comes in, prevents the quiet endpoint-shifting that makes a marginal or ambiguous result look stronger in hindsight than it actually was. This is a documentation and discipline choice, not a spending decision.
Honest, appropriately sized power calculations. A smaller study, sized and interpreted honestly for what it actually is, produces more defensible data than a larger study whose sample size was never calculated at all and is simply assumed to be adequate. Underpowered studies aren't inherently dishonest, treating an underpowered result as conclusive is where the real problem starts, and that's a design and reporting choice, not a budget one.
Sequencing spend around the highest-uncertainty question. Resource-constrained teams often spread a limited budget evenly across a study plan, rather than front-loading spend on the single experiment most likely to validate or kill the entire program. Answering the riskiest, most consequential assumption first, even with a smaller, sharper study, is more capital-efficient than a broader study design that leaves the biggest open question unanswered until the budget has already run out.
Using shared and outsourced infrastructure without letting it dictate your design
India's biotech infrastructure is genuinely fragmented, over 95 bio-incubators exist, but only a small number offer end-to-end facilities, and startups often have to work across multiple cities to complete a single development program. Centralized shared resources, like ICMR's National Animal Resource Facility for Biomedical Research, exist precisely because individual companies at small and mid-scale can't reasonably build this capability themselves.
The mistake isn't relying on shared or outsourced infrastructure, that's the accepted, economically rational model at this scale. The mistake is failing to plan protocol timelines around facility availability from the start, which turns a genuinely cost-saving choice into a scheduling crisis.
There's a real, instructive example of a founder team navigating exactly this tension deliberately: Eyestem, discussed publicly at BioWave 2026, chose to focus on diseases requiring smaller numbers of therapeutic cells specifically to reduce manufacturing and preclinical complexity within cost constraints, while still holding rigorous standards. The company's own leadership offered an important caution alongside that success: the culture of extreme efficiency that gets a company through early preclinical stages can become a genuine limitation once it moves into later-stage development, where different planning is required. Resource-driven design choices aren't a problem in themselves; the risk is making them once and never revisiting them as the program matures.
A practical sequence for capital-constrained teams
Identify your riskiest assumption first and design the smallest experiment that could genuinely kill or validate it.
Build randomization, blinding, and a pre-specified endpoint into every study by default, regardless of size, since none of these cost significantly more.
Size your study honestly and report it honestly; a smaller, well-characterized study is more valuable than a larger one whose power was never actually calculated.
Map your protocol to real facility availability before finalizing it, so outsourced or shared infrastructure is a planned dependency, not a discovered bottleneck.
Revisit resource-driven design choices at each stage gate, rather than carrying an early-stage efficiency mindset unexamined into later, higher-stakes decisions.
The real differentiator isn't budget size
The founders who raise their next round successfully are the ones whose data held up when an investor's technical diligence team or a regulator finally looked closely. This has far more to do with disciplined design choices made early than with the size of the check that funded the study.
Hexaura Solutions helps funded biotech teams design preclinical protocols that are rigorous by construction, without requiring the budget of an in-house preclinical division.
Comments